Відмінності між версіями «Of Cancer published by John Wiley Sons Ltd on behalf of»

Матеріал з HistoryPedia
Перейти до: навігація, пошук
м
м
Рядок 1: Рядок 1:
−
p-values relate to comparison [http://campuscrimes.tv/members/twist42brush/activity/630240/ Tions at opposite locations (red) and within-object places (blue) plotted against] between all three groups. Next, we compared outcome between (i) patients with mutation heterogeneity affecting either KRAS, BRAF, PI3K or TP53 across metastatic deposits (n 5 13), (ii) [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p  65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets. Multiple vs. single mets. TP53 mutations PIK3CA mutations KRAS or BRAF mutations (mut vs. double wt) Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95  CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700
+
Kaplan eier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer [https://www.medchemexpress.com/fosamprenavir-calcium-salt.html GW433908G web] Comparing patients harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) [https://www.medchemexpress.com/Ganetespib.html STA-9090 manufacturer] Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95  CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 [https://dx.doi.org/10.1186/1479-5868-9-35 title= 1479-5868-9-35] patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p [https://dx.doi.org/10.1002/ejsp.2064 title= ejsp.2064] 58 months, p  65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets.

Версія за 12:48, 7 грудня 2017

Kaplan eier survival curves illustrating differences in time to relapse (left panels) and disease-specific survival (right panels) after liver surgery for metastatic colorectal cancer GW433908G web Comparing patients harboring no mutations to patients harboring intraindividual mutation heterogeneity across either KRAS, BRAF, TP53 or PI3K and patients revealing at least one homogenous but no heterogeneous mutation in either gene (a). double wt) STA-9090 manufacturer Chemotherapy1 1.08 0.93 1.55 2.00 1.73 0.92 1.12 2.34 0.39 95 CI (0.71, 1.65) (0.62, 1.40) (0.97, 2.48) (1.21, 3.29) (1.11, 2.68) (0.61,1.42) (0.63, 1.97) (1.50, 3.66) (0.23, 0.64) p values 0.720 0.726 0.064 0.007 0.015 0.720 0.700 title= 1479-5868-9-35 patients harboring a homogeneous mutation in at least one gene across all metastatic deposits and with no heterogeneous mutation and (iii) patients with no mutations across either gene. Comparing all three groups, univariate analysis revealed asignificant different TTR (median of 4 vs. 5 vs. 15 months, p title= ejsp.2064 58 months, p 65 years) Sex (male vs. female) Nodal status of primary (N1 vs. N0) Synchronous vs. metachronous mets.

Отримано з http://istoriya.soippo.edu.ua/index.php?title=Of_Cancer_published_by_John_Wiley_Sons_Ltd_on_behalf_of&oldid=262055